Abstract

Introduction: Epidermal growth factor (EGF) is one of the major growth factors involved in the re-epithelialization and remodeling phase of wound healing. In addition, local and sustained presence of EGF has been shown to accelerate wound healing. However, previous attempts to develop EGF for clinical applications have been limited by its short circulating half-life. We have previously developed a technique utilizing directed evolution to engineer EGF mutants (mtEGFs) with enhanced and persistent binding affinity to human EGFR (hEGFR).

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.